Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model

Código QR

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model

Roberto Lozano,1 Nieves Domeque,2 Alberto-Fermin Apesteguia3 1Pharmacy Department, 2Psychiatry Department, Hospital Real Nuestra Señora de Gracia, 3Pharmacy Department, Hospital Clinico Universitario "Lozano Blesa", Zaragoza, Spain Purpose: The aim of this work was to analyze th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lozano R, Domeque N, Apesteguia AF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/65d59f21e1be470db87d2a3712f6d0fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
por: Lozano R, et al.
Publicado: (2013)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson PB
Publicado: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost C, et al.
Publicado: (2014)

ModVizPop: A shiny interface for empowering teams to perform interactive pharmacokinetic/pharmacodynamic simulations
por: Pavan Vaddady, et al.
Publicado: (2021)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
por: Frost C, et al.
Publicado: (2018)

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study
por: Tompson DJ, et al.
Publicado: (2014)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui Y, et al.
Publicado: (2013)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
por: Nagelschmitz J, et al.
Publicado: (2014)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
por: Cui Y, et al.
Publicado: (2014)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein&ndash;Barr virus disease
por: Heather&nbsp;E Vezina, et al.
Publicado: (2009)

A population pharmacokinetic‐pharmacodynamic model of YH12852, a highly selective 5‐hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation
por: Siun Kim, et al.
Publicado: (2021)

A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
por: Kalman DS, et al.
Publicado: (2015)

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
por: Matsumoto K, et al.
Publicado: (2016)

Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin – a model-based study
por: Edrich T, et al.
Publicado: (2015)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Xia Pu, et al.
Publicado: (2021)

Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation
por: Saeed Alqahtani, et al.
Publicado: (2021)

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
por: Helen Humphries, et al.
Publicado: (2021)

Pharmacokinetics and skin-tissue penetration of daptomycin in rats
por: Matsumoto K, et al.
Publicado: (2015)

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study
por: Wang X, et al.
Publicado: (2013)

Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects
por: Rambiritch V, et al.
Publicado: (2016)

Population pharmacokinetics of olprinone in healthy male volunteers
por: Kunisawa T, et al.
Publicado: (2014)

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole
por: Patel C, et al.
Publicado: (2011)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost C, et al.
Publicado: (2018)

Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study
por: François Riglet, et al.
Publicado: (2020)

Comparisons of Four Protein-Binding Models Characterizing the Pharmacokinetics of Unbound Phenytoin in Adult Patients Using Non-Linear Mixed-Effects Modeling
por: Heajin Jun, et al.
Publicado: (2020)

Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin
por: Tjandrawinata RR, et al.
Publicado: (2015)

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics
por: Mohamed A. Kamal, et al.
Publicado: (2021)

Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically‐based pharmacokinetic model
por: Khaled Abduljalil, et al.
Publicado: (2021)

Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma
por: Li Zhang, et al.
Publicado: (2021)

Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision‐making—A workshop summary
por: Daphney Jean, et al.
Publicado: (2021)

A first‐in‐human study of KMRC011, a potential treatment for acute radiation syndrome, to explore tolerability, pharmacokinetics, and pharmacodynamics
por: Eunsol Yang, et al.
Publicado: (2021)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti VV, et al.
Publicado: (2013)

Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms
por: Hermann R, et al.
Publicado: (2014)

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers
por: Farr SJ, et al.
Publicado: (2015)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Ekaterina Gibiansky, et al.
Publicado: (2021)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Chetan Rathi, et al.
Publicado: (2021)

Mechanisms and the clinical relevance of complex drug–drug interactions
por: Roberts AG, et al.
Publicado: (2018)

Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study
por: Yi Tao, et al.
Publicado: (2021)

Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
por: Andreas Port, et al.
Publicado: (2021)

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
por: van Rossem K, et al.
Publicado: (2013)